PTG1 et PTG3 sont des polymères cationiques avec histidine qui permettent d’obtenir une transfection ADN très efficace et peu toxique de différents types de cellules de mammifères.
PTG1-plus est un dérivé de PTG1 certifié BPF qui est très performant pour la bioproduction de protéines et de virus recombinants obtenus à partir de transfection transitoire de cellules de HEK293 et CHO-S.
Bioproduction de particules virales
A protocol has been developed for the bioproduction of AAV and Lentiviruses on an industrial scale in bioreactors of 200 to 400 liters. The production of viruses with PTG1-plus was much more effective than that obtained with competing transfection reagents, particularly with respect to the high level of complete viral particles.
This scaling up is essential to hope to reduce the costs of production and achieve more reasonable drug prices.
The results were presented at the annual conference of the European Society of Genetic and Cell Therapy (ESGCT) held in Barcelona from 22 to 25 October 2019. Poster P063 and P082
Following these results, Genethon has entered into a license agreement for the use of PTG1-plus. Yposkesi, the leader in Europe for the large-scale production of viral vectors for gene therapy, has also concluded a contract to supply PTG1-plus.